Are serum protein biomarkers derived from proteomic analysis useful in screening for trisomy 21 at 11-13 weeks?

Fetal Diagnosis and Therapy

Volumn 30, Issue 1, 2011, Pages 53-59

  Mastricci, Anna Lucia ^a,b   Akolekar, Ranjit ^a   Kuppusamy, Ramesh ^a   Ahmed, Mustafa ^a   Nicolaides, Kypros H ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Biochemical markers; First trimester screening; Proteomics; Trisomy 21

Indexed keywords

AFAMIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CERULOPLASMIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CLUSTERIN; EPIDERMAL GROWTH FACTOR; FETUIN A; GLYCOPROTEIN; PIGMENT EPITHELIUM DERIVED FACTOR; PLASMA PROTEIN; PREALBUMIN; PREGNANCY ASSOCIATED PLASMA PROTEIN A; UNCLASSIFIED DRUG;

ANEUPLOIDY; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FETUS; FIRST TRIMESTER PREGNANCY; GENETIC SCREENING; HUMAN; MATERNAL AGE; NUCHAL TRANSLUCENCY MEASUREMENT; PRENATAL SCREENING; PRIORITY JOURNAL; PROTEOMICS; TRISOMY 21;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DOWN SYNDROME; FEMALE; HUMANS; MASS SCREENING; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PRENATAL DIAGNOSIS; PROTEOMICS;

EID: 80051780734     PISSN: 10153837     EISSN: 14219964     Source Type: Journal    
DOI: 10.1159/000324310     Document Type: Article

References (28)

1. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH: UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Lancet 1998; 352: 343-346. (Pubitemid 28352196)
2. Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH: Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin, and pregnancy associated plasma protein-A. Ultrasound Obstet Gynecol 2008; 31: 618-624.
3. Nicolaides KH: Turning the pyramid of prenatal care. Fetal Diagn Ther 2011, in press.
4. Huber LA: Is proteomics heading in the wrong direction? Nat Rev Mol Cell Biol 2003; 4: 74-80. (Pubitemid 36077259)
5. Silberring J, Ciborowski P: Biomarker discovery and clinical proteomics. Trends Analyt Chem 2010: 29: 128-140.
6. Robinson HP, Fleming JE: A critical evaluation of sonar 'crown-rump length' measurements. Br J Obstet Gynaecol 1975; 82: 702-710.
7. Busch A, Michel S, Hoppe C, Driesch D, Claussen U, von Eggeling F: Proteome analysis of maternal serum samples for trisomy 21 pregnancies using ProteinChip arrays and bioinformatics. J Histochem Cytochem 2005; 53: 341-343. (Pubitemid 40344070)
8. Nagalla SR, Canick JA, Jacob T, Schneider KA, Reddy AP, Thomas A, Dasari S, Lu X, Lapidus JA, Lambert-Messerlian GM, Gravett MG, Roberts CT Jr, Luthy D, Malone FD, D'Alton ME: Proteomic analysis of maternal serum in down syndrome: Identification of novel protein biomarkers. J Proteome Res 2007; 6: 1245-1257. (Pubitemid 46724021)
9. Kolialexi A, Tsangaris GT, Papantoniou N, Anagnostopoulos AK, Vougas K, Bagiokos V, Antsaklis A, Mavrou A: Application of proteomics for the identification of differentially expressed protein markers for Down syndrome in maternal plasma. Prenat Diagn 2008; 28: 691-698.
10. Koster MP, Pennings JL, Imholz S, Rodenburg W, Visser GH, de Vries A, Schielen PC: Bead-based multiplexed immunoassays to identify new biomarkers in maternal serum to improve first trimester Down syndrome screening. Prenat Diagn 2009; 29: 857-862.
11. Koster MP, Pennings JL, Imholz S, Rodenburg W, Visser GH, de Vries A, Schielen PC: Proteomics and Down syndrome screening: A validation study. Prenat Diagn 2010; 30: 1039-1043.
12. Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH: First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: Impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 2008; 31: 493-450.
13. Wright D, Kagan KO, Molina FS, Gazzoni A, Nicolaides KH: A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol 2008; 31: 376-383.
14. Kosak ST, Groudine M: Gene order and dynamic domains. Science 2004; 306: 644-647. (Pubitemid 39440904)
15. Anderson NL, Anderson NG: The human plasma proteome: History, character, and diagnostic prospects. Mol Cell Proteomics 2002; 1:845-867.
16. Echan LA, Tang HY, Ali-Khan N, Lee K, Speicher DW: Depletion of multiple highabundance proteins improves protein profiling capacities of human serum and plasma. Proteomics 2005; 5: 3292-3303. (Pubitemid 41192036)
17. Brand J, Haslberger T, Zolg W, Pestlin G, Palme S: Depletion efficiency and recovery of trace markers from a multiparameter immunodepletion column. Proteomics 2006; 6: 3236-3242. (Pubitemid 43886142)
18. Gundry RL, White MY, Nogee J, Tchernyshyov I, Van Eyk JE: Assessment of albumin removal from an immunoaffinity spin column: Critical implications for proteomic examination of the albuminome and albumin-depleted samples. Proteomics 2009; 9: 2021-2028.
19. Garbis S, Lubec G, Fountoulakis M: Limitations of current proteomics technologies. J Chromatogr A 2005; 1077: 1-18.
20. Tambor V, Fucíková A, Lenco J, Kacerovský M, Rehácek V, Stulík J, Pudil R: Application of proteomics in biomarker discovery: A primer for the clinician. Physiol Res 2010; 59: 471-497.
21. Wang P, Bouwman FG, Mariman EC: Generally detected proteins in comparative proteomics -a matter of cellular stress response? Proteomics 2009; 9: 2955-2966.
22. Petrak J, Ivanek R, Toman O, Cmejla R, Cmejlova J, Vyoral D, Zivny J, Vulpe CD: Déjá vu in proteomics. A hit parade of repeatedly identified differentially expressed proteins. Proteomics 2008; 8: 1744-1749. (Pubitemid 351678270)
23. Jeong DH, Kim HK, Prince AE, Lee DS, Kim YN, Han J, Kim KT: Plasma proteomic analysis of patients with squamous cell carcinoma of the uterine cervix. J Gynecol Oncol 2008; 19: 173-180.
24. Jackson D, Craven RA, Hutson RC, Graze I, Lueth P, Tonge RP, Hartley JL, Nickson JA, Rayner SJ, Johnston C, Dieplinger B, Hubalek M, Wilkinson N, Perren TJ, Kehoe S, Hall GD, Daxenbichler G, Dieplinger H, Selby PJ, Banks RE: Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer. Clin Cancer Res 2007; 13: 7370-7379.
25. Doustjalali SR, Yusof R, Govindasamy GK, Bustam AZ, Pillay B, Hashim OH: Patients with nasopharyngeal carcinoma demonstrate enhanced serum and tissue ceruloplasmin expression. J Med Invest 2006; 53: 20-28.
26. Pendyala G, Trauger SA, Siuzdak G, Fox HS: Quantitative plasma proteomic profiling identifies the vitamin E binding protein afamin as a potential pathogenic factor in SIV induced CNS disease. J Proteome Res 2010; 9: 352-358.
27. Mallick P, Kuster B: Proteomics: A pragmatic perspective. Nat Biotechnol 2010; 28: 695-709.
28. Tu C, Rudnick PA, Martinez MY, Cheek KL, Stein SE, Slebos RJ, Liebler DC: Depletion of abundant plasma proteins and limitations of plasma proteomics. J Proteome Res 2010; 9:4982-4991.